> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Symbiomix NDA for Treating Bacterial Vaginosis
- URL: https://www.fdaweb.com/symbiomix-nda-for-treating-bacterial-vaginosis/
- Published: 2017-01-19T12:00:00.000Z
- Updated: 2026-09-14T22:01:26.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5137767

Symbiomix has submitted an NDA for Solosec (secnidazole oral granules) for treating bacterial vaginosis (BV). The company describes Solosec as a potent, next-generation, investigational 5-nitroimidazole antibiotic with enhanced pharmacokinetic properties. In clinical trials Solosec demonstrated efficacy for treating BV with only a single, oral, two-gram dose, it says. BV is the most prevalent gynecological infection in the U.S. among women ages 15 to 44.